drugset / Trial / NCT04707196
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with hormone therapy in Indian women with advanced breast cancer. Participants must have hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer and must live in India. For each participant, the study could last up to eight months and may include up to eight visits to the study center.
Timeline
- Start
- 2021-02-22
- Primary completion
- 2023-01-09
- Completion
- 2023-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |
| Background | Letrozole | Other / unclassified | — | Oral |